Actively Recruiting
Efficacy and Safety Study of 610 in Patients With Severe Asthma
Led by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Updated on 2026-01-07
480
Participants Needed
1
Research Sites
166 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
CONDITIONS
Official Title
Efficacy and Safety Study of 610 in Patients With Severe Asthma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to give written informed consent before joining the study
- Male or female adults aged 18 to 75 years at consent
- Diagnosed with asthma for at least one year before screening
- History of asthma treatment with inhaled corticosteroids and at least one other control medication for 6 months or more before screening
You will not qualify if you...
- Having any known serious lung condition other than asthma
- Severe asthma attack within 4 weeks before randomization
- Presence of eosinophilic diseases other than asthma
- Known severe or significant heart disease
- Other serious medical conditions not controlled by standard treatment
- Active infections of Hepatitis B, Hepatitis C, or HIV at screening
- Allergy or intolerance to monoclonal antibody treatments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
Q
Qinghong Zhou, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here